Advancements in the clinical application of gene methylation for early cancer detection
Frontiers in Epigenetics and Epigenomics · 2024
DOI: 10.3389/freae.2024.1430294 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Epigenetics and Epigenomics, 2024. Verfasst von Xin Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This review provides an overview of common assays used to screen for gene methylation and early biomarkers of methylation in various cancers. DNA methylation, one of the most well-studied epigenetic modifications, plays a crucial role in normal cell and tissue development. It is increasingly utilized as a biomarker for early cancer and precancerous lesion detection. In this review, we describe common methods associated with gene methylation, including bisulfite sequencing PCR (BSP), pyrosequencing technology (PYR), methylation-specific polymerase chain reaction (MS-PCR/MSP), methylation-sensitive high-resolution melting (MS-HRM), methylation sensitive single nucleotide primer extension (MS-SnuPE), Epityper, Droplet digital PCR (ddPCR), methylation-sensitive restriction enzyme (MSRE) analysis, COBRA and PacBio SMRT sequencing. Additionally, we summarize methylation markers and their sample types for early cancer screening, focusing on colorectal cancer, hepatocellular carcinoma, gastric cancer, pancreatic cancer, esophageal cancer (digestive system), lung cancer (respiratory system), breast cancer, ovarian cancer, cervical cancer (female reproductive system), bladder cancer, and prostate cancer (urinary system). Furthermore, we discuss the recent detection of methylation biomarkers in clinical samples such as blood, urine, sputum, feces, and tissues. The aim of this review is to summarize early methylation biomarkers that are expected or have already been clinically applied. For future large-scale studies or the integration of available methylome level data, the discovery of sufficiently sensitive clinical biomarkers is essential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
- College of Laboratory Medicine, Dalian Medical University, Dalian, Liaoning, China.
- Department of Laparoscopic Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Zitieren
APA
Xu, X., Guo, Y., Liu, M., Hu, Y., & Li, S. (2024). Advancements in the clinical application of gene methylation for early cancer detection. Frontiers in Epigenetics and Epigenomics. https://doi.org/10.3389/freae.2024.1430294
Vancouver
Xu X, Guo Y, Liu M, Hu Y, Li S. Advancements in the clinical application of gene methylation for early cancer detection. Frontiers in Epigenetics and Epigenomics. 2024. doi:10.3389/freae.2024.1430294
BibTeX
@article{Xu2024,
author = {Xu, Xin and Guo, Yanru and Liu, Mulin and Hu, Yunxiang and Li, Shijun},
title = {Advancements in the clinical application of gene methylation for early cancer detection},
journal = {Frontiers in Epigenetics and Epigenomics},
year = {2024},
doi = {10.3389/freae.2024.1430294}
}
EUVIMED